CordenPharma has acquired Ancora Pharmaceuticals based in Woburn, MA. Ancora offers a carbohydrate synthesis technology platform from its chemistry research facilities. The acquisition enhances CordenPharma’s capabilities in the manufacture and supply of complex synthetic molecules.

Ancora’s expertise in carbohydrate synthes will be merged with CordenPharma’s process development, scale-up and cGMP manufacturing capabilities to supply synthetic carbohydrates for all applications, including glycoconjugate vaccine antigens, immunomodulatory therapeutics, tissue targeting/drug delivery motifs, nutraceuticals, analytical reagents and standards, diagnostic reagents, and defined content for glycomics research.
  
Ancora and CordenPharma will provide carbohydrate synthesis and production needs from early stage discovery research through to commercial cGMP manufacturing. Both CordenPharma and Ancora will serve customers out of Ancora’s Woburn facility, with newly expanded capabilities for transition to large scale cGMP manufacturing at CordenPharma’s facilities in the U.S. and in Europe.